Combining Active and Passive DNA Hypomethylation

Abroad (travel likely)RecruitingPHASE2

Conditions

Myelodysplastic Syndromes · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Aalborg University Hospital, Aalborg, Denmark
Contact: Study coordinator (Marianne Tang Severinsen, MD, PhD) · m.severinsen@rn.dk · +45 97666745
Aarhus University Hospital, Aarhus, Denmark
Contact: Study coordinator (Anne S Roug, MD) · annrou@rm.dk
Rigshospitalet, Copenhagen, Denmark
Contact: Study coordinator (Kirsten Grønbæk, Prof., MD) · kirsten.groenbaek@regionh.dk · +45 35 45 60 86
Contact: Study coordinator (Krista Smidt Bech, BSc, Nurse) · krista.smidt.bech.01@regionh.dk · +45 35 45 60 80
Stine Ulrik Mikkelsen, MD, PhD (Sub-investigator)
Ali Al-Mousawi, MD (Sub-investigator)
Herlev University Hospital, Copenhagen, Denmark
Contact: Study coordinator (Bo Kok Mortensen, MD, PhD) · bo.kok.mortensen@regionh.dk · +45 38686483
Odense University Hospital, Odense, Denmark
Zealand University Hospital, Roskilde, Denmark
Sahlgrenska University Hospital, Gothenburg, Sweden
Contact: Study coordinator (Hege Gravdahl Garelius, MD) · hege.garelius@vgregion.se
Skåne University Hospital, Lund, Sweden
Contact: Study coordinator (Lars Nilsson, MD, PhD) · lars.nilsson@skane.se
Karolinska University Hospital, Stockholm, Sweden
Contact: Study coordinator (Eva Hellström-Lindberg, Prof., MD) · eva.hellstrom-lindberg@ki.se
Uppsala University Hospital, Uppsala, Sweden
Contact: Study coordinator (Elisabeth Ejerblad, MD) · elisabeth.ejerblad@akademiska.se

Study leads

Kirsten Grønbæk, Prof., MD
Study Director
Rigshospitalet, Denmark
Stine Ulrik Mikkelsen, MD, PhD
Principal Investigator
Rigshospitalet, Denmark
Ali Al-Mousawi, MD
Principal Investigator
Rigshospitalet, Denmark

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

Leukemia · Myelodysplastic Syndromes · Myeloproliferative Syndrome

Abroad (travel likely)Recruiting

Hartford, United States · Portland, United States

National Longitudinal Cohort of Hematological Diseases

Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia

Abroad (travel likely)Recruiting

Tianjin, China